CMS' Changes to Reimbursement for Biosimilars
Rebates and Medicare Part D
The Cost of Biologics and Biosimilars
Alternative Payment Models and Patient Care
Patient Education on Coverage for Biologics and Biosimilars
The Exceptions Process and its Effect on Patients
Biosimilars, Payers, and Formulary Changes
Barriers to Biosimilars for Oncology Patients
Patient Savings From Biosimilars
Patient Awareness of Biosimilars and Loyalty to Branded Drugs
Seth Ginsberg: Patient Assistance Programs and Biologic Drugs
Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, addresses the importance of patient assistance programs.
Seth Ginsberg: The CMS Proposal to Treat Biosimilars as Generics for Cost-Sharing
Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, discusses CMS' proposal to treat biosimilars as generics for the purpose of cost-sharing.
Seth Ginsberg: What Patients Need to Know About Biosimilars
Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, explains what patients should know about biosimilar therapies.
Scott Lassman: Drug Pricing Legislation
Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, describes trends in state legislation on drug pricing and industry reaction to such laws.
Scott Lassman: Changes to the FDA Under Scott Gottlieb, MD
Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, describes how the FDA has changed under its current leadership.
Seth Ginsberg: Educating Patients on Biosimilars
Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, reflects on physician efforts to educate patients about biosimilars.
Scott Lassman: Industry Takeaways from Allergan's Patent Transfer
Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, responds to Allergan's recent transfer of patents to a soverign entity, and gives 2 takeaways for industry.
Scott Lassman: Follow-on Biologics and the "Regulatory Dead Zone"
Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, explains how the upcoming transition of follow-on biologics to regulation as biosimilars could create a "regulatory dead zone."
Seth Ginsberg: Biologics and Prior Authorization
Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, discusses the impact of prior authorization requirements on patients and providers.
Seth Ginsberg: Step Therapy's Effect on Patients
Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, explains how "fail-first" policies, or step therapy, affect patients.
Seth Ginsberg: Patient Access to Biologics
Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, discusses the challenges that patients face in accessing biologic medicines.
Scott Lassman: Products to be Regulated as Biologics by 2020
Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, explains which products currently regulated as drugs will be transitioned to regulation as biologics by 2020.
Ha Kung Wong: Biosimilars and the STRONGER Patents Act
Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper and Scinto, discusses how the STRONGER Patents Act could affect biosimilars.
Ha Kung Wong: Congress and the BPCIA
Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper and Scinto, discusses whether Congress might revisit the Biologics Price Competition and Innovation Act (BPCIA).
Scott Lassman: Follow-On Products Versus Biosimilars
Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, explains differences between follow-ons and biosimilars.
Scott Lassman: Waiving the Single Shared REMS Requirement
Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, explains the burden to the health system when FDA waives a single shared REMS requirement.
Dr Paul P. Doghramji: Using Biosimilars in Practice
Paul P. Doghramji, MD, FAAFP discusses using biosimilars in practice.
Dr Paul P. Doghramji: Prescribing Biosimilars in IBD
Paul P. Doghramji, MD, FAAFP, discusses whether he has begun to prescribe biosimilars for patients with inflammatory bowel disease.
Dr Ira Klein: Biosimilars and the Cost of Care
Ira Klein, MD, senior director of health care quality strategy for the strategic customer group at Johnson & Johnson Health Care Services, explains how biosimilars will help to control costs.
Dr Jeff Patton: Biosimilars and OCM
Jeff Patton, MD, president and CEO of Tennessee Oncology, discusses how biosimilars fit into the Oncology Care Model (OCM).